mRNA– tag –
-
Moderna-Merck Cancer Vaccine Enters Phase 3, mRNA Therapeutics LNP Manufacturing Scales Beyond 17 L/hr, Rare Metabolic Disease Drugs Nearing Approval Studies
BioProcess International USA Overview Six key developments are shaping mRNA therapeutics beyond COVID-19 vaccines: Moderna and Merck's personalized cancer vaccine has advanced to Phase 3 trials, and rare metabolic disease drugs like mRNA... -
Exosome Treatments in Aesthetics Remain FDA Unapproved with Safety Warnings: Emphasizing Evidence-Based Approaches
Aesthetic Med Guide USA Overview The U.S. FDA has reiterated that no exosome products are approved for aesthetic purposes and has issued a public safety alert against the use of unapproved products. This article details the scientific ba... -
Global Biomanufacturing Leaders Lonza, Fujifilm Diosynth, AGC Biologics Expand CGT & mRNA Capacities
Healthcare Ranking USA Overview Major CDMOs including Lonza, Fujifilm Diosynth Biotechnologies, and AGC Biologics are aggressively expanding global manufacturing capacities for biologics, cell & gene therapies (CGT), and mRNA product... -
Comprehensive Review Spotlights Lipid Nanoparticles as a Transformative Drug Delivery System
International Journal of Scientific Research and Technology (Int. J. Sci. R. Tech.) India Overview The International Journal of Scientific Research and Technology has published a detailed review positioning lipid nanoparticles (LNPs) as ... -
AI/ML Frameworks Drive Rapid Optimization of Lipid Nanoparticle Formulations for Advanced Drug Delivery
Frontiers Switzerland Overview Lipid Nanoparticles (LNPs) are a cornerstone for advanced drug and nucleic acid delivery, yet their rational design presents a formidable multivariate challenge. New research harnesses AI/Machine Learning (... -
mRNA-LNP: The Non-Viral Platform Revolutionizing In Vivo CAR-T Cell Engineering
Journal of Controlled Release Unknown Overview The convergence of messenger RNA (mRNA) and lipid nanoparticle (LNP) delivery technology is poised to transform in vivo CAR-T cell engineering. This non-viral platform promises significant a... -
Lonza Pioneers Adaptive Manufacturing for In Vivo mRNA-LNP Therapies, Unlocking CRISPR for Rare Diseases and Cancer Immunotherapy
BioXconomy Switzerland Overview Lonza has unveiled an adaptive manufacturing platform designed to accelerate the development and production of in vivo mRNA-lipid nanoparticle (LNP) delivery systems. This breakthrough technology promises ... -
Beyond LNPs: Polymer Delivery Systems Promise Enhanced Stability, Reduced Toxicity, and Targeted Delivery for mRNA Therapeutics
MDPI Switzerland Overview Polymer-based delivery systems are rapidly emerging as a promising alternative to conventional lipid nanoparticles (LNPs) for mRNA therapeutics. While LNPs have achieved significant clinical success, particularl... -
Precision Oncology Unleashed: Tumor-Specific Promoters and Nanocarriers Drive Next-Gen Gene Therapy, LNP-Based mRNA/siRNA Therapies Paving the Way
MDPI Switzerland Overview Precision cancer gene therapy is being transformed by the integration of tumor-specific promoters and nanodelivery systems, significantly enhancing therapeutic specificity. A range of nanocarriers, including LNP... -
Voyager Therapeutics Receives FDA IND Clearance for VY1706, First Tau-Targeted Gene Therapy, to Begin Alzheimer’s Disease Phase 1 Trial
Cell & Gene Therapy Review USA Overview Voyager Therapeutics announced that its Investigational New Drug (IND) application for VY1706, a tau-targeted gene therapy for Alzheimer's disease, has been cleared by the FDA. VY1706 is a potent a...
